Replies to post #86270 on Biotech Values

[DewDiligence]

Abgenix characterized the D-mab (f/k/a/ AMG 162) royalty due from AMGN as a mid-single-digit % of sales. The XenoMouse license for D-mab happened so long ago (1999) I had to check if it was AMGN or Immunex who did the deal.